- 1
Soga J, Yakuwa Y.
Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407
reported cases.
J Hepatobiliary Pancreat Surg.
1998;
5
312-319
- 2
Wermers R A, Fatourechi V, Kvols L K.
Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors.
Mayo Clin Proc.
1996;
71
1030-1038
- 3
Boden G.
Glucagonomas and insulinomas.
Gastroenterol Clin North Am.
1989;
18
831-845
- 4
Wermers R A, Fatourechi V, Wynne A G. et al .
The glucagonoma syndrome. Clinical and pathologic features in 21 patients.
Medicine (Baltimore).
1996;
75
53-63
- 5
McEntee G P, Nagorney D M, Kvols L K. et al .
Cytoreductive hepatic surgery for neuroendocrine tumors.
Surgery.
1990;
108
1091-1096
- 6
Norton J A, Warren R S, Kelly M G. et al .
Aggressive surgery for metastatic liver neuroendocrine tumors.
Surgery.
2003;
134
1057-1063
- 7
Henn A R, Levine E A, McNulty W. et al .
Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief
of neuroendocrine syndromes.
AJR.
2003;
181
1005-1010
- 8
Gupta S, Yao J C, Ahrar K. et al .
Hepatic artery embolization and chemoembolization for treatment of patients with metastatic
carcinoid tumors: the M. D. Anderson experience.
Cancer J.
2003;
9
261-267
- 9
Cahlin C, Friman S, Ahlman H. et al .
Liver transplantation for metastatic neuroendocrine tumor disease.
Transplant Proc.
2003;
35
809-810
- 10
Le Treut Y P, Delpero J R, Dousset B. et al .
Results of liver transplantation in the treatment of metastatic neuroendocrine tumors.
A 31-case French multicentric report.
Ann Surg.
1997;
225
355-364
- 11
Leong W L, Pasieka J L.
Regression of metastatic carcinoid tumors with octreotide therapy: two case reports
and a review of the literature.
J Surg Oncol.
2002;
79
180-187
- 12
Oberg K, Kvols L, Caplin M. et al .
Consensus report on the use of somatostatin analogs for the management of neuroendocrine
tumors of the gastroenteropancreatic system.
Ann Oncol.
2004;
15
966-973
- 13
Oberg K.
Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
Ann Oncol.
2001;
12 (Suppl 2)
S111-S114
- 14
Faiss S, Pape U F, Bohmig M. et al .
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide,
interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic
tumors- the International Lanreotide and Interferon Alfa Study Group.
J Clin Oncol.
2003;
21
2689-2696
- 15
Bajetta E, Ferrari L, Procopio G. et al .
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine
tumours.
Ann Oncol.
2002;
13
614-621
- 16
Fjallskog M L, Granberg D P, Welin S L. et al .
Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.
Cancer.
2001;
92
1101-1107
- 17
Kwekkeboom D J, Teunissen J J, Bakker W H. et al .
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine
gastroenteropancreatic tumors.
J Clin Oncol.
2005;
23
2754-2762
- 18
Safford S D, Coleman R E, Gockerman J P. et al .
Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in
98 patients.
Cancer.
2004;
101
1987-1993
PD Dr. med. Andreas Türler
Klinik und Poliklinik für Allgemein-, Viszeral-, Thorax- und Gefäßchirurgie
Universitätsklinikum Bonn · 53105 Bonn
eMail: tuerler@uni-bonn.de
